Theravance Biopharma R&D IP LLC

General

Total Cases8

Active Cases2

Patents583

CourtsD. New Jersey D. Delaware E.D. Pennsylvania

TypeNPE

Elite Ratings

--

theravance-biopharma

theravance-biopharma

Ratings

Experience

Grade

Trend

DCT

L1

A

PTAB

--

--

--

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	LETTER ORDER Granting Plaintiffs' [285] joint request for an extension of the deadline to file the motions to seal and redactions; the Parties shall file an omnibus motion to seal and their redactions on 10/29/2024. Signed by Judge Karen M. Williams on 10/16/2024. (mag) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	LETTER ORDER Granting Plaintiffs' [285] joint request for an extension of the deadline to file the motions to seal and redactions; the Parties shall file an omnibus motion to seal and their redactions on 10/29/2024. Signed by Judge Karen M. Williams on 10/16/2024. (mag) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	LETTER ORDER Granting Plaintiffs' [285] joint request for an extension of the deadline to file the motions to seal and redactions; the Parties shall file an omnibus motion to seal and their redactions on 10/29/2024. Signed by Judge Karen M. Williams on 10/16/2024. (mag) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialities Ltd 1:24-CV-08558 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialities Ltd 1:24-CV-08558 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialities Ltd 1:24-CV-08558 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)
10/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialities Ltd 1:24-CV-08558 ( D. NJ )	CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024) CONSOLIDATION ORDER: The 926 Action and the 8558 Action are consolidated for all purposes, including discovery, case management, and trial, subject to further Order of the Court; all filings in the Consolidated Actions shall use the 926 Action Caption; all filings going forward shall be made in the 926 Action; and the 8558 Action shall be administratively terminated by the Clerk's Office; the Consolidated Actions will follow the amended schedule of the 926 Action. Signed by Judge Karen M. Williams on 10/15/2024. (sms2) (Entered: 10/16/2024)